Your browser doesn't support javascript.
loading
Health system costs of rheumatic heart disease care in South Africa.
Hellebo, Assegid G; Zuhlke, Liesl J; Watkins, David A; Alaba, Olufunke.
Afiliación
  • Hellebo AG; Health Economics Unit, Faculty of Health Sciences, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. Assegid2013@gmail.com.
  • Zuhlke LJ; Division of Paediatric Cardiology, Department of Paediatrics, Faculty of Health Sciences, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa.
  • Watkins DA; Division of Cardiology, Department of Medicine, Faculty of Health Sciences, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Alaba O; Division of General Internal Medicine, Department of Medicine, School of Medicine, University of Washington, Seattle, USA.
BMC Public Health ; 21(1): 1303, 2021 07 03.
Article en En | MEDLINE | ID: mdl-34217236
BACKGROUND: Rheumatic Heart Disease (RHD) is a disease of poverty that is neglected in developing countries, including South Africa. Lack of adequate evidence regarding the cost of RHD care has hindered national and international actions to prevent RHD related deaths. The objective of this study was to estimate the cost of RHD-related health services in a tertiary hospital in the Western Cape, South Africa. METHODS: The primary data on service utilisation were collected from a randomly selected sample of 100 patient medical records from the Global Rheumatic Heart Disease Registry (the REMEDY study) - a registry of individuals living with RHD. Patient-level clinical data, including, prices and quantities of medications and laboratory tests, were collected from the main tertiary hospital providing RHD care. All annual costs from a health system perspective were estimated in 2017 (base year) in South African Rand (ZAR) using a combination of ingredients and step-down costing approaches and later converted to United States dollars (USD). Step-down costing was used to estimate provider time costs and all other facility costs such as overheads. A 3% discount rate was also employed in order to allow depreciation and opportunity cost. We aggregated data to estimate the total annual costs and the average annual per-patient cost of RHD and conducted a one-way sensitivity analysis. RESULTS: The estimated total cost of RHD care at the tertiary hospital was USD 2 million (in 2017 USD) for the year 2017, with surgery costs accounting for 65%. Per-patient, average annual costs were USD 3900. For the subset of costs estimated using the ingredients approach, outpatient medications, and consumables related to cardiac catheterisation and heart valve surgery were the main cost drivers. CONCLUSIONS: RHD-related healthcare consumes significant tertiary hospital resources in South Africa, with annual per-patient costs higher than many other non-communicable and infectious diseases. This analysis supports the scaling up of primary and secondary prevention programmes at primary health centers in order to reduce future tertiary care costs. The study could also inform resource allocation efforts and provide cost estimates for future studies of intervention cost-effectiveness.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiopatía Reumática Tipo de estudio: Health_economic_evaluation Límite: Humans País/Región como asunto: Africa Idioma: En Revista: BMC Public Health Asunto de la revista: SAUDE PUBLICA Año: 2021 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiopatía Reumática Tipo de estudio: Health_economic_evaluation Límite: Humans País/Región como asunto: Africa Idioma: En Revista: BMC Public Health Asunto de la revista: SAUDE PUBLICA Año: 2021 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Reino Unido